Oxurion NV Logo

Oxurion NV

Acquires majority stakes in European pharmaceutical subcontractors.

OXUR | BR

Overview

Corporate Details

ISIN(s):
BE0974487192
LEI:
549300VWY8KVDFKLDM59
Country:
Belgium
Address:
Gaston Geenslaan 1, 3001 Heverlee

Description

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-15 18:00
OXUR-PR_Voting-rights-ENG_20251015.pdf
English 273.4 KB
2025-10-15 18:00
OXUR-PR_Voting-rights-NED_20251015.pdf
Dutch 315.3 KB
2025-10-02 18:00
OXUR-Transparency-Notification-EN-20251002.pdf
English 352.2 KB
2025-10-02 18:00
OXUR-Transparency-Notification-NL-20251002.pdf
Dutch 378.2 KB
2025-09-30 18:00
OXUR GLOBAL - Financial report 30-06-2025 (EN) FINAL.pdf
English 412.9 KB
2025-09-30 18:00
OXUR GLOBAL - Financial report 30-06-2025 (NL) FINAL.pdf
Dutch 420.8 KB
2025-09-30 18:00
OXUR_Publish-H1-2025-results_EN.pdf
English 211.4 KB
2025-09-30 18:00
OXUR_Publication-H1-2025-resultats_FR.pdf
French 161.8 KB
2025-09-30 18:00
OXUR_Publicatie-H1-2025-resultaten_NL.pdf
Dutch 211.0 KB
2025-09-08 18:00
OXUR-Transparency-Notification-EN-20250903.pdf
English 371.9 KB
2025-09-08 18:00
OXUR-Transparency-Notification-NL-20250903.pdf
Dutch 396.3 KB
2025-09-01 18:00
OXUR-Contrat-atlas-crypto-EN-20250901.pdf
English 190.2 KB
2025-09-01 18:00
OXUR-Contrat-atlas-crypto-FR-20250901.pdf
French 125.2 KB
2025-09-01 18:00
OXUR-Contrat-atlas-crypto-NL-20250901-1.pdf
Dutch 214.2 KB
2025-09-01 18:00
OXUR-Transparency-Notification-EN-20250901.pdf
English 1.2 MB

Automate Your Workflow. Get a real-time feed of all Oxurion NV filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oxurion NV

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oxurion NV via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-07 Bareldam SA Close relation Buy 1,180,555 1,700,000.00 EUR
2021-09-30 Lavinia D. Clay 2009 Revocable Trust Close relation Other 2,766,337 5,601,002.52 EUR

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.